Monday , October 23 2017
Home / KEEP BUT DO NOT DISPLAY / Did You Know / EASD: Better Diabetes Outcomes with New Drug Combo

EASD: Better Diabetes Outcomes with New Drug Combo

Data presented at the European Association for the Study of Diabetes meeting revealed a fixed-dose insulin degludec/liraglutide combination resulted in greater blood glucose control in type 2 diabetes patients compared with either monotherapy. The insulin degludec/liraglutide combination treatment resulted in a greater proportion of subjects with blood glucose values within target ranges vs. the individual components in insulin degludec or liraglutide for all pre- and all postprandial values. King A. Abstract #243. EASD, Sept. 16-19, Vienna